GlobeNewswire Inc | Aug 3, 2021 08:30AM EDT

August 03, 2021

CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Steven Bellon, Ph.D., Senior Vice President of Drug Discovery, is scheduled to participate in a panel at the 2021 Wedbush PacGrow Healthcare Virtual Conference, which is being held from August 10-11.

Panel Details:Title: Bullseye Targeted Oncology Part 2Panel date and time: Wednesday, August 11, 10:20 a.m. ET

Members of the Foghorn management team will also host investor meetings during the conference.

A live webcast of the panel can be accessed under Events & Presentations in the Investors section of the Companys website, www.foghorntx.com.

About Foghorn Therapeutics

Foghorn Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

Media Contact:

Fanny Cavali, Foghorn Therapeutics fcavalie@foghorntx.com

Gregory Kelley, Ogilvy gregory.kelley@ogilvy.com

Investor Relations Contact:

Allan Reine, Foghorn Therapeutics areine@foghorntx.com

Hans Vitzthun, LifeSci Advisors617-430-7578hans@lifesciadvisors.com